DeepMed Research

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Atezolizumab
Drug: RO6874281
Drug: Bevacizumab

First Posted Date: 2017-02-24

Last Posted Date: 2023-02-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 69

Registration Number: NCT03063762

Locations: 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇫🇷
Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes, Lyon, France
🇮🇹
Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia, Modena, Emilia-Romagna, Italy

and more 20 locations

Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: Obinutuzumab

First Posted Date: 2017-02-23

Last Posted Date: 2020-04-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT03059251

Locations: 🇦🇷
Clínica Peuyrredón, Buenos Aires, Argentina
🇦🇷
Hospital Municipal Teodoro Alvarez, Buenos Aires, Argentina
🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Expanded Access to RXDX-105 for Cancers With RET Alterations

Conditions: Cancers With RET Alterations

First Posted Date: 2017-02-14

Last Posted Date: 2019-04-26

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT03052569

Locations: 🇺🇸
Www.Ignyta.Com, San Diego, California, United States

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: Risdiplam

First Posted Date: 2017-02-02

Last Posted Date: 2018-10-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT03040635

Locations: 🇺🇸
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

Phase 2

Completed

Conditions: Macular Degeneration, Age-Related
Neovascularization, Choroidal

Interventions: Drug: Faricimab
Drug: Ranibizumab
Drug: Sham Procedure

First Posted Date: 2017-02-01

Last Posted Date: 2021-01-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 76

Registration Number: NCT03038880

Locations: 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸
California Retina Consultants, Bakersfield, California, United States
🇺🇸
Rand Eye, Deerfield Beach, Florida, United States

and more 22 locations

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: RO7239361
Drug: Placebo for RO7239361

First Posted Date: 2017-02-01

Last Posted Date: 2020-12-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 166

Registration Number: NCT03039686

Locations: 🇺🇸
University of Massachusetts Memorial Childrens Medical Center; Department of Neurology, Worcester, Massachusetts, United States
🇺🇸
Rush University Medical Center - PPDS, Chicago, Illinois, United States
🇺🇸
Nationwide Childrens Hospital; Research Institute at Nationwide Childrens Hospital, Columbus, Ohio, United States

and more 41 locations

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B

Phase 1

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: RO7062931
Drug: Placebo
Drug: Immune Modulator

First Posted Date: 2017-01-31

Last Posted Date: 2020-12-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 119

Registration Number: NCT03038113

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇨🇳
Chang Gung Medical Foundation Linkou Branch, Taoyuan City, Taiwan

and more 16 locations

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Atezolizumab
Drug: Atezolizumab Placebo
Drug: Bevacizumab

First Posted Date: 2017-01-31

Last Posted Date: 2023-02-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1301

Registration Number: NCT03038100

Locations: 🇺🇸
Columbus NCORP, Columbus, Ohio, United States
🇺🇸
Ohio State University, Arthur James Cancer Hospital, Columbus, Ohio, United States
🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States

and more 264 locations

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Phase 1

Completed

Conditions: RET-altered Non Small Cell Lung Cancer
Thyroid Diseases
Thyroid Neoplasm
Thoracic Neoplasms
Carcinoma, Bronchogenic
Head and Neck Neoplasms
Carcinoma
Neoplasms, Germ Cell and Embryonal
Digestive System Neoplasm
Carcinoma, Neuroendocrine

Interventions: Drug: pralsetinib (BLU-667)

First Posted Date: 2017-01-31

Last Posted Date: 2024-04-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 589

Registration Number: NCT03037385

Locations: 🇩🇪
Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany
🇳🇱
Universitair Medisch Centrum Groningen, Groningen, Netherlands
🇺🇸
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States

and more 69 locations

A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [^14C]-Risdiplam

First Posted Date: 2017-01-30

Last Posted Date: 2018-10-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6

Registration Number: NCT03036501

Locations: 🇳🇱
Pra International Group B.V, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy